Compare Davita Inc (DVA) vs Victoria's Secret & Co (VSXY) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Davita Inc vs Victoria's Secret & Co — how do they compare? Davita Inc trades at $179.02 (market cap $11.72B), while Victoria's Secret & Co trades at $94 (market cap $7.95B). The key difference: Davita Inc is the larger of the two by market cap, and Victoria's Secret & Co is trading nearer its 52-week high, Davita Inc nearer its low. Which is the better fit depends on your goals.
| DVA | VSXY | |
|---|---|---|
Market Cap | $11.72B | $7.95B |
Sector | Health | Consumer Cyclical |
52-Week High | $240.96 | $99.97 |
52-Week Low | $103.87 | $21.34 |
Enterprise Value | $24.44B | $10.59B |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
DaVita (DVA) trades at $183.77, up 1.72% today, with a mixed technical picture showing bearish moving averages but bullish oscillators. The company reported strong Q2 2026 earnings of $4.02 per share, beating estimates, driven by volume growth. Revenue reached $13.64 billion in 2025, with a net income margin of 6.05%. Analyst consensus is a Buy with a $232.25 price target, though technical signals are bearish overall.
The outlook for DVA is cautiously optimistic, supported by earnings beats and volume growth, but risks include reimbursement pressure and high debt levels. The stock offers potential upside to the consensus target, yet investors face headwinds from margin compression and technical bearishness.
Victoria's Secret (VSXY) trades at $98.54, up 5.37% on the day and near its 52-week high, reflecting strong momentum. Recent earnings beats, including Q1 2026 EPS of $0.60 versus $0.32 expected, and positive cash flow projections for 2026 signal operational improvement. Technical indicators show a bullish trend with support at $95 and resistance at $101, though RSI levels suggest overbought conditions. The company's focus on data-driven marketing and international expansion, particularly in China, supports growth narratives.
The outlook is cautiously optimistic with a buy-rated analyst consensus and a $91 price target, though current valuation metrics like a P/E of 39.26 appear elevated. Risks include competitive pressures in apparel retail and reliance on consumer spending trends. Net cash flow turned positive in 2026 forecasts, but margin volatility remains a watch point for sustained shareholder value.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Davita Inc
DaVita is the largest provider of dialysis services in the United States, boasting market share that eclipses 35% when measured by both patients and clinics. The firm operates over 3,100 facilities worldwide, mostly in the U.S., and treats over 240,000 patients globally each year. Government payers dominate U.S. dialysis reimbursement. DaVita receives approximately 69% of U.S. sales at government (primarily Medicare) reimbursement rates, with the remaining 31% coming from commercial insurers. However, while commercial insurers represented only about 10% of the U.S. patients treated, they represent nearly all of the profits generated by DaVita in the U.S. dialysis business.
Read more on DVA →About Victoria's Secret & Co
Victoria's Secret & Co is a specialty retailer of lingerie, pajamas, and beauty products with prestige fragrances and body care. It serves customers at its Lingerie and Beauty stores around the globe and online enabling them to shop the brand anywhere and anytime.
Read more on VSXY →
